{"id":1662,"date":"2020-04-14T10:29:23","date_gmt":"2020-04-13T21:29:23","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=1662"},"modified":"2020-06-22T10:06:32","modified_gmt":"2020-06-21T21:06:32","slug":"patient-with-cll-may-have-had-longer-covid-19-incubation-period","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=1662","title":{"rendered":"Patient With CLL May Have Had Longer COVID-19 Incubation Period"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Patient With CLL May Have Had Longer COVID-19 Incubation Period<\/h1>\n

[\/vc_custom_heading][vc_column_text]A case report out of China suggested that clinical and biochemical data of COVID-19 might have been partly masked in a patient with chronic lymphocytic leukemia (CLL).<\/p>\n

Specifically, a patient presenting in Wenzhou, China, with CLL who was diagnosed with COVID-19 appeared to have a disease incubation period of about 25 days. The patient had traveled to Wuhan between January 12-18, 2020, before traveling back to Wenzhou and self-isolating for 14 days. He presented to the hospital on February 16 after four days of symptoms.<\/p>\n

\u201cWithout the complete travel history, COVID-19 infection was not initially suspected, because his whole blood cell and lymphocyte counts were high because of his chronic lymphocytic leukemia masking a potential infection,\u201d the case report authors wrote. \u201cHowever, the attending physician noticed that although symptoms could be the result of a recurrent infection, his chest CT scan resembled that of a patient with COVID-19.\u201d<\/p>\n

After testing positive, the patient began treatment with reduced dose of oral chlorambucil to treat his condition due to CLL and received the recommended treatment for COVID-19 in China: nebulized \u03b1-interferon (5 million IUs) twice per day, intravenous human immunoglobulin (20 g) once per day, and intravenous methylprednisolone (40 mg) every 12 hours.<\/p>\n

The patient had relapsing fever PaO2<\/sub>\/FiO2<\/sub> less than 300 mm Hg and a sequential organ failure assessment score of 4. Noninvasive ventilation therapy was given until dyspnea subsided on day 8 of treatment. Treatment was changed to low-dose methylprednisone every 12 hours with oral chlorambucil twice per day for the next 4 days.<\/p>\n

Follow-up CT showed substantial improvement and the patient\u2019s temperature also returned to normal. A repeat COVID-19 test showed the patient remained positive for the virus and an additional 7 days of observation was recommended.<\/p>\n

Based on this case, the authors said better diagnostic strategies could be used for diagnosis, and individuals with compromised immune status may be subject to a longer disease incubation period.<\/p>\n

\u201cIt remains uncertain whether the combination of chemotherapy, corticosteroids, \u03b1-interferon, and immunoglobulins could work synergistically in patients with\u00a0chronic lymphocytic leukemia<\/a>\u00a0and COVID-19,\u201d they wrote.<\/p>\n

Originally published on Cancer Therapy Advisor<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

A case report out of China suggested that clinical and biochemical data of COVID-19 might have been partly masked in a patient with chronic lymphocytic leukemia (CLL).<\/p>\n","protected":false},"author":1,"featured_media":1663,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17,22],"tags":[],"class_list":["post-1662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","category-covid19"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/04\/doctor-patient_G_586032874-860x557-1.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/1662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1662"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/1662\/revisions"}],"predecessor-version":[{"id":1664,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/1662\/revisions\/1664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/1663"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}